Real‐world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate‐to‐severe plaque psoriasis - Rompoti, Natalia; Stefanaki, Irene; Panagakis, Pantelis; Papoutsaki, Marina; Politou, Maria; Vavouli, Charitomeni; Befon, Angeliki; Kousta, Fiori; Lazou, Eleni; Zaimi, Maria; Koumprentziotis, Ioannis‐Alexios; Chasapi, Vasiliki; et al. (Journal of the European Academy of Dermatology and Venereology, 2025)